Objective: To test the hypothesis that human amniotic fluid mesenchymal stem cells contain a unique epigenetic signature in imprinting centers of H19, SNRPN, and KCNQ1OT1 during in vitro cell culture. Materials and Methods: By bisulfite genomic sequencing, we analyzed the imprinting centers of three imprinted genes (including H19, SNRPN, and KCNQ1OT/) in a total of six single-cell clones of human amniotic fluid mesenchymal stem cells at cell passages 7, 8, 9, and 10 during in vitro cell culture. Results: The imprinting centers of H19 and KCNQ1OT1 showed hypermethylation at passage 7 in all single-cell clones of human amniotic fluid mesenchymal stem cells, and there was no significant change in DNA methylation patterns during in vitro cell culture. The imprinting centers of SNRPN showed variable methylation patterns at passage 7 in six single-cell clones, and DNA methylation patterns varied during in vitro cell culture from passages 8 to 10. Conclusion: In conclusion, human amniotic fluid mesenchymal stem cells contain a unique epigenetic signature during in vitro cell culture. H19 and KCNQ1OT1 possessed a substantial degree of hypermethylation status, and variable DNA methylation patterns of SNRPN was observed during in vitro cell culture of human amniotic fluid mesenchymal stem cells. Our results urge further understanding of epigenetic status of human amniotic fluid mesenchymal stem cells before it is applied in cell replacement therapy.
Introduction
Mesenchymal stem cells with the potential to differentiate to adipocytes, chondrocytes, and osteocytes have been isolated from human amniotic fluid [1e4] . Amniotic fluid mesenchymal stem cells (AFMSCs) could be successfully induced to differentiate into various tissue types, such as skin, cartilage, cardiac tissue, nerve, muscle, bone, kidney, and endothelium [4e8] . As AFMSCs are able to differentiate into lineages representative of all three germ layers but do not form tumors when injected in vivo [4, 9] and are less likely to raise ethical concerns of their generation, AFMSCs have many potential applications in regenerative medicine [4e6, 8, 10] . Tissue engineered products from mesenchymal amniocytes had been used for diaphragm reconstruction in lambs [11] , trachea reconstruction in lambs [12] , and sternum repair in rabbits [13] .
Recently, the potential applications of AFMSCs for cellbased therapy had also been demonstrated in a sheep model by using autologous stem cell transplantation in a sheep fetus [14] . These autologous cells derived from AFMSCs showed widespread organ migration in fetal tissues including liver, heart, placenta, membrane, umbilical cord, adrenal gland, and muscle. Although not proven in humans, the autologous human AFMSCs may offer an alternative means to ameliorate prenatal congenital disease [8] and could make it possible to have an autologous cell source for adult diseases, such as heart valve diseases [15] . However, considering the heterogeneity of the cells found in amniotic fluid, we have further isolated and characterized single-cell clones from amniotic fluid specimens. The clonal amniotic fluid-derived stem cells can express characteristics of both mesenchymal and neural stem cells [2] .
A central assumption of Mendel's laws of inheritance is that genes originating from maternal and paternal genomes are equally expressed in the offspring; however, there are some exceptions [16] . In some disorders, such as BeckwitheWiedemann syndrome (BWS), PradereWilli syndrome, and Angelman syndrome (AS), the sex of the transmitting parent plays a role in the expression of the phenotype in his or her affected children. This led to the discovery of parental imprinted genes: a gene expressed only from the paternally inherited chromosome is maternally imprinted (the maternal allele is inactivated); similarly, a gene expressed only from the maternally inherited chromosome is paternally imprinted (the paternal allele is inactivated).
Progenies of assisted reproductive technologies are reported to be at higher risk for an altered imprinting status, leading to BWS [17, 18] and AS [19, 20] . In BWS, methylation abnormalities are found in two differentially methylated regions (DMR) that are located in 11q15: DMR1 of H19 and DMR2 of KCNQ10T1 [20] . Defect of the SNRPN imprinting control center/DMR in chromosome 15q11.2 is part of the pathogenesis of AS.
Disturbed expression of particular imprinted genes has been linked to fetal growth and development abnormalities as well as other human diseases [21] . Previous studies on sheep [22] and mouse embryos [23, 24] , and mouse stem cells [25] have shown that they are prone to epigenetic variation and lose normal imprinted gene expression when cultured in vitro. It has been reported that the DNA methylation patterns of human embryonic stem cells (hESCs) are distinct from those of other cells [26] . Importantly, abnormal CpG island methylation occurs during in vitro differentiation of hES. The more passages embryonic stem cells experienced, the more they appeared to differ from other cells of the same line that underwent fewer passages [27] .
Given the observations between assisted reproductive technologies and human epigenetic disorders, we hypothesized that human AFMSCs might have unique epigenetic characters during in vitro cell culture. To fill the current knowledge gap on AFMSCs, herein we study the epigenetic characteristics of CpG islands of three imprinted genes (H19, SNRPN, and KCNQ1OT1) on human AFMSC, especially focusing on the differences among various single-cell clones and the effect of in vitro cell culture on epigenetic changes of imprinted genes on human AFMSCs. A better understanding of the epigenetic characteristics of AFMSCs and their epigenetic changes during in vitro cell culture will give us more information for future applications of these AFMSCs in disease therapy and tissue engineering.
Material and methods

Patient enrollment
We recruited patients who were given prenatal care and planning to deliver at the Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital (CGMH), Taiwan. This study was approved by the Institute Review Board of CGMH (IRB #97-1341A3). Patients were enrolled only after written informed consents were obtained.
Specimen collection
Two amniotic fluid samples (AF20451744 and AF21251150) were obtained after amniocentesis in CGMH [3] . Amniocentesis for medical reasons was performed between 16 and 20 weeks of pregnancy, and a total of 20 mL of amniotic fluid was aspirated from the amniotic sac transabdominally under sono-guide. The fetal cells were cultured in Chang medium, and the adhering cells were used for chromosomal studies. The nonadhering cells suspended in Chang medium for the first 3 days were collected for stem cells isolation and culture [1] .
Culture of single-cell clones of AFMSCs
AFMSCs were cultured in alpha-modified minimum essential medium (Hyclone, Logan, UT) supplemented with 20% fetal bovine serum (Hyclone) and 4 ng/mL basic fibroblast growth factor (R&D Systems, Minneapolis, MN) and incubated at 37 C in a humidified atmosphere with 5% CO 2 . Isolation of single-cell clones of AFMSCs was performed using cloning cylinders (Sigma, St. Louis, MO) on cell colonies at the first 2 weeks of growth on plates. These single-cell clones of AFMSCs were successively expanded and confirmed to have mesenchymal stem cell surface antigen markers by flow cytometry and differentiation abilities into osteoblasts, chondrocytes, and adipocytes, as in our previous report [28] . In this study, AFMSCs were further characterized for the pluripotent markers of Oct4 (R&D Systems) and Nanog (R&D Systems) by flow cytometry.
Chromosome study of two amniotic fluid samples
The karyotypes of two amniotic fluid samples were analyzed using a standard G-banding technique.
Single-cell clones of AFMSC DNA extraction and bisulfite treatment of DNA Genomic DNA from human AFMSC was extracted using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer's recommendations. The quality and quantity of DNA were analyzed by Nanodrop. Aliquots of 1 mg of DNA from AFMSCs underwent bisulfite conversion by EpiTect Bisulfite Kit (Qiagen).
Bisulfite PCR and sequencing
The eluted DNA samples (after bisulfite conversion) were amplified using polymerase chain reaction (PCR) primers specific for the DMRs of the imprinted genes being studied (Fig. 1) , including H19, SNRPN, and KCNQ1OT1, as previously described [16] . The primers used for bisulfite sequencing are as follows:
TOPO cloning of bisulfite PCR product and DNA sequencing PCR products were cloned into the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA) and transformed into competent cells. Individual clones from at least two independent reactions were selected for sequencing. The DNA sequence results were then analyzed for the methylation status of the CpG dinucleotide [16] .
Analysis of different passages of AFMSC
We studied and tracked cells in four different passages: passages 7, 8, 9, and 10.
Results
Chromosome study of two amniotic fluid samples
The karyotypes of both amniotic fluid samples were normal female karyotypes (46,XX).
Culture and characterization of single-cell clones of AFMSCs
Six single-cell clones of AFMSCs from two amniotic fluid specimens were established. Three clones were from sample AF20451744 and three clones were from sample AF21251150. Besides the MSC surface markers that were expressed (data not shown), the six single-cell clones of human AFMSCs were also strongly positive for Oct4 and Nanog pluripotent markers (Fig. 2) . The osteogenetic differentiation capacity was identified by von Kossa staining of all six single-cell clones of human AFMSCs (Fig. 3) .
Epigenetic characteristics of CpG islands of imprinted gene H19 on six single-cell clones derived from human AFMSCs and the effect of in vitro cell culture on epigenetic changes of imprinted gene H19 on human AFMSCs.
In the six single-cell clones of human AFMSCs, the DNA methylation pattern shows a unique epigenetic signature of hypermethylation in CpG islands of the imprinted gene H19. In passage 7, the methylation rate was 79e98% in six singlecell clones of amniotic fluid stem cells (Table 1) . Further studies on different passages (passages 8e10) showed no significant methylation changes during in vitro cell culture. We found that in passages 8e10 of six single-cell clones of AFMSCs during in vitro cell culture, almost all were hypermethylated with methylation rates of 65e96% with only two exceptions (50% and 39%) ( Table 1) .
Epigenetic characteristics of CpG islands of imprinted gene SNRPN on six single-cell clones derived from human AFMSCs and the effect of in vitro cell culture on epigenetic changes of imprinted gene SNRPN on human AFMSCs.
In the six single-cell clones of human AFMSCs, the DNA methylation patterns showed variable methylation on CpG islands of the imprinted gene SNRPN. In passage 7, the methylation rate is 32e47% in six single-cell clones of amniotic fluid stem cell (Table 2) . Further studies on different passages (passages 8e10) of six single-cell clones of amniotic fluid stem cells shows there were variable methylation pattern changes during in vitro cell culture with methylation rates of 21e88% (Table 2) .
Epigenetic characteristics of CpG islands of imprinted gene KCNQ1OT1 in six single-cell clones derived from human AFMSCs and the effect of in vitro cell culture on epigenetic changes of imprinted gene KCNQ1OT1 on human AFMSCs.
In the six single-cell clones of human AFMSCs, the DNA methylation patterns all showed a unique epigenetic signature of hypermethylation in the CpG island of the imprinted gene KCNQ1OT1 with only one exception. In passage 7, the methylation rates ranged from 96% to 99% in five single-cell clones of AFMSCs; only one clone had a significantly lower methylation rate of 39% (Table 3) . Further studies on different passages (passages 8e10) show that there were no significant methylation pattern changes during in vitro cell culture. We found that during in vitro cell culture in passages 8e10 of six single-cell clones of amniotic fluid stem cells, all of them were hypermethylated with methylation rates of 71e99% (Table 3) . Table 1 Methylation pattern on imprinting center of H19.
H19
C (%) B (%)   H19-C1P7  93  7  H19-C1P8  90  10  H19-C1P9  90  10  H19-C1P10  96  4  H19-C2P7  98  2  H19-C2P8  50  50  H19-C2P9  83  17  H19-C2P10  81  19  H19-C3P7  79  21  H19-C3P8  69  31  H19-C3P9  39  61  H19-C3P10  79  21  H19-C4P7  94  6  H19-C4P8  94  6  H19-C4P9  93  7  H19-C4P10  96  4  H19-C5P7  79  21  H19-C5P8  93  7  H19-C5P9  69  31  H19-C5P10  65  35  H19-C6P7  92  8  H19-C6P8  70  30  H19-C6P9  69  31  H19-C6P10  78  22 C ¼ methylated; B ¼ unmethylated; C ¼ clone; P ¼ passage. Table 2 Methylation pattern on imprinting center of SNRPN. C1P7  32  68  SNRPN-C1P8  80  20  SNRPN-C1P9  66  34  SNRPN-C1P10  77  23  SNRPN-C2P7  36  64  SNRPN-C2P8  37  63  SNRPN-C2P9  21  79  SNRPN-C2P10  26  74  SNRPN-C3P7  34  66  SNRPN-C3P8  50  50  SNRPN-C3P9  88  12  SNRPN-C3P10  46  54  SNRPN-C4P7  46  54  SNRPN-C4P8  78  22  SNRPN-C4P9  33  67  SNRPN-C4P10  96  4  SNRPN-C5P7  47  53  SNRPN-C5P8  65  35  SNRPN-C5P9  82  18  SNRPN-C5P10  49  51  SNRPN-C6P7  32  68  SNRPN-C6P8  45  55  SNRPN-C6P9  52  48  SNRPN-C6P10 41 59
can be found in amniotic fluid [33, 34] . Amniocentesis is a widely accepted method of prenatal diagnosis, and the extra samples can be used to isolate AFMSCs, which has raised fewer ethical issues than other fetal stem cell sources, while still representing a good candidate for cell therapeutic applications and tissue engineering [1] . The potential use of AFMSCs for tissue regeneration were shown to be successful in animal models, including cartilage [35] , smooth muscle [36] , and cardiomyocyte cell sheet formation [37] . DNA methylation, which is responsible for gene silencing, is an epigenetic system that determines the specific characteristics of many cells, including stem cells. Until now, most studies have focused on the epigenetic changes on embryonic stem cells; however, the studies on DNA methylation patterns of human AFMSCs are limited. It had been reported that the DNA methylation patterns of hESCs are distinct from those in other cells, which may further our understanding of the mechanism behind stem cells' pluripotency [26] . Another report proposes gene-specific differences in the stability of imprinted loci in hESCs and disrupted DNA methylation as one potential mechanism [38] . Moreover, in vitro hESCs differentiation causes epigenetic abnormalities such as hypermethylation of CpG islands [27] . Recent studies suggest that genetic lesions and epigenetic instability including abnormal DNA methylation in cancer-related genes occur during long-term passage of hESCs [39] . The more passages the embryonic stem cells experienced, the more they appeared to differ from other cells of the same line that underwent fewer passages. This issue is important because alterations in DNA methylation have been associated with cancer and human genetic disorders [40] . Also, it is believed that the genome/ epigenome damage may elevate the risk for adverse health outcomes during various stages of life, contributing to problems with fertility and fetal development [41] . Because in vitro cell culture may change the epigenetic characteristics of the hESCs, it makes therapeutic cloning more challenging because of concerns that these epigenetic changes could affect human health, which can limit our applications of these in vitro cell culture cells in human therapies, cell transplantation, and tissue repair.
To our knowledge, this is the first study on the DNA methylation patterns on DMRs of imprinting genes (H19, SNRPN, and KCNQ1OT1) in human single-cell clones of AFMSCs during in vitro cell culture. In our study, we found that there is a hypermethylation pattern in the imprinting center of H19, and there are no significant changes in methylation patterns in most passages of AFMSCs during in vitro cell culture. In a previous report, abnormal hypermethylation within the IGF2/H19 imprinting center was found in monkey ESC lines [42] . In mouse multipotent germ line stem cells, the imprinting center of H19 is hypermethylated during in vitro cell culture [43] . In a review article on human ESC cells, variable epigenetic stability is observed [44] . In our study, there is variable methylation pattern on the imprinting center of SNRPN in single-cell clones of AFMSCs, and there are also variable changes in methylation patterns during in vitro cell culture. In a previous report, the SNURF/SNRPN imprinting centers are differentially methylated in monkey ESC lines [42] . Another report on methylation patterns of the Snurf/ Snrpn cluster in mouse ES cells exhibited notable stability during in vitro manipulation [45] . In human ESCs, SNRPN is highly epigenetically stable [44] . In our study, there are altered methylation patterns (hypermethylation) at the imprinting center of KCNQ1OT1 in single-cell clones of AFMSCs, and there are no significant changes in methylation patterns in all passages during in vitro cell culture. In a previous report, KCNQ1OT1 is highly epigenetically stable in human ESCs [44] . Based on these findings, we know that DNA methylation patterns at the imprinting center of imprinting genes might be quite different in different source of stem cells and species.
Our study on the epigenetics of AFMSCs is an interesting initial look into what might be done for these stem cells that can potentially be applicable in therapies and tissue engineering. From the results of our study, we know about the altered DNA methylation pattern (hypermethylation) of H19 and KCNQ1OT1 of human single-cell clones of AFMSCs, which might cause therapeutic cloning to face enormous challenges. On the other hand, we found the variable epigenetic status of SNRPN in human AFMSCs during in vitro cell culture. These findings may have an impact on the suitability of AFMSCs for therapeutic use. Therefore, periodic monitoring of these cell lines may be required before they are used in in vivo applications. 
